CREB3L1 and fatty liver disease: Previously, gene regulatory network analysis has revealed that CREB3L1 is a master regulator for fibrosis-associated genes, which together with our newly found genetic association with liver steatosis suggests that CREB3L1 might be a promising novel drug target for liver steatosis and the additional development of fibrosis [33].